$MDHI Sept. 17, 2012 /PRNewswire via COMTEX/ -- Medical

New Post Public Reply Private Reply Replies (0) Message Board
goarmy123

$MDHI Sept. 17, 2012 /PRNewswire via COMTEX/ -- Medical Alarm Concepts Holding, Inc. (OTCQB: MDHI.PK), manufacturer of the MediPendant(TM) two-way voice personal medical alarm, sent the following letter to all shareholders outlining recent accomplishments and future plans.

Dear Shareholders of Medical Alarm Concepts Holding, Inc.:

It's been a very long road for Medical Alarm Concepts Holding, Inc. (MDHI) since going public several years ago. The Company was organized with the idea of revolutionizing the personal medical alarm sector through the introduction of a unique two-way, speak and listen through the medical pendant technology. For much of our history the company has failed to realize its growth potential. These reasons include a lack of adequate initial capital to execute a truly robust marketing plan, and structural balance sheet issues relating to our initial money raise that resulted in a toxic structure of our convertible debt, which in turn handicapped our ability to raise additional funds needed to make the company a success.

I am writing to you today to explain what we have done to rectify these issues and to let you know about the dramatic turnaround our business has realized over the past few months. What we plan to express in this shareholder letter is not that we are planning to turn our business around, but rather that we have already turned the business around and that we are experiencing extremely strong sales growth rates. Additionally, we wish to express to you that we are very quickly approaching our revenue breakeven point. This turnaround has been very dramatic and as we move into our busiest sales period of the year, our confidence level has never been higher.

Here's a summary of what's happening at the company:

Debt Restructuring - Over the past 12 months, we have worked closely with our convertible debt holders in order to negotiate an adequate settlement that returned the debt holder's capital with a profit, while still maintaining the integrity of our capital structure. We are very happy to report to our shareholders this process is now complete with all of the debt now consolidated under a single entity that has a significant interest in the long-term viability of the company. As a result of these negotiations a large portion of the convertible debt has now been outright cancelled, 165 million highly dilutive warrants have been cancelled, and as we announced last week, all of the Series A and Series B Convertible Preferred stock has been retired. We strongly believe that for the first time in the company's history there is now a workable capital structure that will allow us to realize the growth potential we initially envisioned.

Credit Line Establishment and Balance Sheet Restructuring - We have been able to inject new funds into the company in a manner that very few small entrepreneurial organizations are able to achieve. We have established an unsecured $750,000 credit line with no features for conversion to either common or preferred stock. It is the type of financing that only much larger companies are able to establish and it has made a huge difference in our ability to maneuver within our market space. With the funds from this credit line we have paid off nearly all of our trade payables, significantly increased our inventory levels, and implemented many of the marketing programs that had been planned but never funded.

Retail and International Presence - Last December we announced the MediPendant would be offered on the E-Commerce platform of one of the largest retailers in the country. This relationship has progressed throughout 2012 and both parties are very happy with the progress achieved. The company also recently announced the initiation of shipments to our first European customer and that we are in negotiations for several other international contracts. These new relationships have not only resulted in significant revenue growth, but have also attracted additional attention and market focus to our unique product offering.

Significant Order Growth - We are very happy to report to our shareholders that the above outlined actions and programs are resulting in very strong growth in orders and revenues. We believe an important aspect of this growth has been the recent implementation of a much more aggressive pay per click Internet campaign, which has thus far yielded strong website clicks and order follow through. Also, we feel the medical alarm market is now beginning to recognize the brand "MediPendant" and this is leading to more inquiries and resulting order flow.

Returning to Fully Reporting SEC Status - Medical Alarm Concepts is a voluntary reporting organization with the Securities & Exchange Commission and thus we are not required to file financials. Transparency is, nevertheless important to us, so we are committed to filing full financials with the SEC as soon as we are able. As we announced in a recent press release, we have informed our accountants to begin preparing the financials in order to return us to fully reporting status. As many of you know, maintaining full reporting is very expensive for small companies and thus late last year, we made the strategic decision to suspend this reporting in order to remain solvent and to continue to implement programs to restore growth. We are very happy to tell our investors we believe this was the right strategy and we believe the growth we are currently experiencing is the result.

Breakeven Mark - It is important to remember that we not only receive revenues for sales of MediPendant personal medical alarm equipment, but also monthly subscription services for the monitoring of these alarms. As we continue to accelerate sales, our recurring monthly revenues continue to grow and we are now quickly reaching the point where these recurring revenues are very close to surpassing our monthly fixed expenses. The exact timing of the company reaching its breakeven point depends on the sustainability of the current growth rate trend, but based on these recent trends we expect to reach profitability by the end of the year. With that said, however, we believe the remaining portion of 2012 represents our busiest period of growth and as a result, we would not be surprised to see a significant up-tick in monthly service contracts during this period. Should this transpire, we could easily reach profitability sooner. Profitability of the company is virtually inevitable considering the dynamics of the recurring monthly revenue model and our current growth trajectories.

Capital Structure - There are currently approximately 631,000,000 outstanding common shares, and as we indicated above, the entire convertible preferred stock has now been retired as have the vast majority of outstanding warrants. Based on the recent closing price of the common shares, our total market capitalization is only approximately $2.5 - $3 million. While we have suffered dilution as a result of the conversions and settlements with convertible debt holders, we have been able to hold this dilution to a minimum, and this will hopefully allow existing shareholders to capitalize on our fast trajectory to profitability.

And more!

http://www.otcmarkets.com/stock/MDHI/news

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 446

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 56

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 250

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 333

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
LG's ASIL D Certification: A Game Changer in Autos

Updated Category News Views 38

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 90

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 104

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 612

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading

Top 5 Most Recently Viewed Articles

SOCi's AI Marketing: Leading G2's Summer 2026 Rankings

Updated Category News Views 12

AI's Rising Star in Enterprise Marketing Here's a tidbit worth chewing over your morning coffee: SOCi Inc., a name that's been buzzing in the enterprise circles, has nailed top spots in G2's Summer 2026 Report. We're talking about leading the charge in AI marketing and localized visibility, territories tough to crack unless you've got serious chops. In a world where...

Continue Reading
AI and the Future of Staffing: A Market Growth Story

Updated Category News Views 344

AI and the Future of Staffing: A Growth Story The staffing services market is on the verge of a major transformation, thanks in large part to advancements in Artificial Intelligence (AI). This evolution is projected to add an astounding USD 236.6 billion to the global staffing services market between 2024 and 2028. During this time, the market is expected to experience a...

Continue Reading
Optical Innovations Unite: OCC and Lightera's New Partnership

Updated Category News Views 317

Strategic Collaboration Between OCC and Lightera Optical Cable Corporation (NASDAQ: OCC) and Lightera, LLC are entering a significant partnership aimed at enhancing their product offerings primarily in the data center and enterprise sectors. This collaboration builds upon their long-term relationship, combining their strengths to create innovative optical connectivity...

Continue Reading
INFINOX Welcomes Artem Gonov as New Chief Technology Officer

Updated Category News Views 148

INFINOX Appoints Artem Gonov as Chief Technology Officer INFINOX, a globally recognized brokerage, has recently appointed Artem Gonov as its new Chief Technology Officer (CTO). This strategic move underlines the company's commitment to enhancing its technology landscape and providing exceptional platforms for its clients. Artem Gonov's Background and Expertise Mr. Gonov...

Continue Reading
George Medicines’ GMRx2 Sets New Standard for Hypertension Care

Updated Category News Views 126

George Medicines Introduces GMRx2 for Hypertension Management Recent findings published in The Lancet highlighted the promising results of a Phase III trial for GMRx2, a novel triple combination pill aimed at managing hypertension. Developed by George Medicines, this medication is making waves in the field of cardiovascular care as it demonstrates significant advancements...

Continue Reading